New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
14:55 EDTBIIB, BIIB, BIIB, AEP, AEP, AEPBiogen to replace American Electric in S&P 100 as of 3/21 close
News For BIIB;AEP From The Last 14 Days
Check below for free stories on BIIB;AEP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
13:41 EDTBIIBCitigroup to hold a conference
Subscribe for More Information
August 27, 2014
09:08 EDTBIIBNektar could see $100M in revenue from Baxter drug, says Roth Capital
Roth Capital believes that Baxter's (BAX) BAX-855 drug delivered compelling Phase III data, and the firm expects the drug to compete effectively against Biogen's (BIIB) Eloctate. Roth expects BAX-855 to launch in 1Q16 and believes it could generate up to $100M in annual revenue for Nektar. The firm keeps a $21 price target and Buy rating on Nektar.
08:21 EDTBIIBNICE recommends Tecfidera for multiple sclerosis
Dimethyl fumarate is recommended as a possible treatment for people with active relapsing-remitting multiple sclerosis that isn't highly active or rapidly evolving severe relapsing-remitting multiple sclerosis, the U.K.'s National Institute for Health and Care Excellence stated in guidance posted to its website. Reference Link
August 26, 2014
11:21 EDTBIIBBiogen added to short term buy list at Deutsche Bank
August 25, 2014
12:06 EDTAEPAmerican Electric reaffirms FY14 operating EPS view $3.35-$3.55, consensus $3.49
American Electric Power announced Brian Tierney, AEP executive vice president and CFO, will present at the Barclays CEO Energy-Power Conference Sept. 3. During the conference, AEP will reaffirm its 2014 operating earnings guidance of $3.35 to $3.55 per share.
August 22, 2014
12:39 EDTBIIBThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
August 20, 2014
07:10 EDTAEPAmerican Electric total return outlook compelling, says Wells Fargo
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use